Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Inverse MSTR Daily Target ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $2.57 (market cap $94.46M), while Vertex Pharmaceuticals Incorporated trades at $508.7 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 1350.3× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| MSTZ | VRTX | |
|---|---|---|
Market Cap | $94.46M | $127.55B |
Volume | 104,717,733 | 1,487,944 |
Sector | Leveraged / Inverse | Health |
52-Week High | $27.92 | $557.96 |
52-Week Low | $2.29 | $407.37 |
Typical Hold Time | 8 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTZ is trading at $2.54, down 4.51% today, with technical indicators showing a bearish trend as moving averages signal selling pressure. The stock lacks key financial ratio data, making fundamental assessment challenging. Recent ETF coverage highlights its inclusion in leveraged/inverse ETF discussions, though specific company performance details are limited.
The outlook remains cautious due to incomplete financial disclosures and bearish technical signals. Investment opportunities depend on forthcoming earnings clarity, while risks include volatility from limited institutional coverage and market sentiment shifts. Investors should await detailed financial updates for informed decisions.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
